Clinical Features, Pathological Features, and Treatment Outcomes of 22 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated with a Humanized CCR4 Antibody (Mogamulizumab) at a Single Institution during a 6-year Period (2012-2018)

Noriaki Kawano,Noriaki Yoshida,Sayaka Kawano,Fumiko Arakawa,Hiroaki Miyoshi,Kyohei Yamada,Kazutaka Nakashima,Shuro Yoshida,Takuro Kuriyama,Taro Tochigi,Takashi Nakaike,Tomonori Shimokawa,Kiyoshi Yamashita,Kousuke Marutsuka,Koichi Mashiba,Ikuo Kikuchi,Koichi Ohshima

Clinical Features, Pathological Features, and Treatment Outcomes of 22 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated with a Humanized CCR4 Antibody (Mogamulizumab) at a Single Institution during a 6-year Period (2012-2018)

2019

Noriaki Kawano
Noriaki Yoshida
Sayaka Kawano
Fumiko Arakawa
Hiroaki Miyoshi
Kyohei Yamada
Kazutaka Nakashima
Shuro Yoshida
Takuro Kuriyama
Taro Tochigi
Takashi Nakaike
Tomonori Shimokawa
Kiyoshi Yamashita
Kousuke Marutsuka
Koichi Mashiba
Ikuo Kikuchi
Koichi Ohshima

Objective To elucidate the clinical impact of humanized CCR4 antibody (mogamulizumab) on adult T-cell leukemia-lymphoma (ATL), we retrospectively analyzed the clinical and pathological features and treatment outcomes of aggressive ATL.

Keywords:

Mogamulizumab
Antibody
CCR4
Diabetes mellitus
Oncology
Pathological
Adult T-cell leukemia/lymphoma
Internal medicine
Cardiology
Medicine
Survival rate
Monoclonal
Retrospective cohort study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations